Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerBiomarker

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2043695

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2043695

Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma), Product (Instruments, Consumables), Application (Diagnostics, R&D), End User (Diagnostic Laboratories), And Region - Global Forecast to 2032

PUBLISHED:
PAGES: 468 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 7150
PDF (5-user License)
USD 8500
PDF (Corporate License)
USD 9650
PDF (Global License)
USD 11000

Add to Cart

Description

Table of Contents

List of Tables

The market for cancer biomarkers is valued at around USD 28.25 billion in 2026 and is forecast to reach USD 54.48 billion by 2032, representing a growth of 11.6%. The market is growing steadily, and hospitals and diagnostic laboratories are focusing on the early detection and accurate diagnosis of diseases to improve patient outcomes.

Scope of the Report
Years Considered for the Study2026-2032
Base Year2025
Forecast Period2026-2032
Units ConsideredValue (USD billion)
SegmentsProfiling Technology, Cancer Type, Product, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries

Factors such as rapid technological advances and the global rise in cancer incidence propel market expansion in the development of cancer biomarkers. However, the main obstacles to this market's expansion are the difficulties in validating cancer biomarkers and the lack of qualified workers.

Cancer Biomarkers Market - IMG1

"The omics technology segment is predicted to showcase the highest CAGR during the forecast period."

The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Omics technology had the highest compound annual growth rate (CAGR) in 2025. This is explained by the growing use of proteomics and genomics in drug discovery and development, as well as by improved cancer diagnostics.

"The breast cancer segment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period."

The market for cancer biomarkers is divided into categories according to the type of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancer types. In the market for cancer biomarkers in 2025, the breast cancer category had the fastest growth rate. Advances in technology, the rising global prevalence of cancer, and the development of cancer biomarkers are two important factors driving this segment's growth.

"The diagnostic laboratories segment accounted for the highest share."

Based on end user, the cancer biomarkers market is segmented into diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes, and other end-users. In 2025, the diagnostic laboratories segment accounted for a larger share of the cancer biomarkers market. The growing number of clinical laboratories worldwide performing cancer biomarker-based diagnostic tests and the rising prevalence of malignancies are responsible for this end-user segment's sizable share.

"Asia Pacific is expected to register the fastest growth rate in the cancer biomarkers market, by region."

The region is witnessing a growth spurt due to several key factors, including expanded healthcare infrastructure, increased healthcare expenditure, and greater modernization of hospital and diagnostic facilities. In addition, rising cancer cases and technological advancements in cancer biomarker development are driving growth in the cancer biomarker market in the Asia Pacific region.

The break-up of profiles of primary participants in the cancer biomarkers market:

  • By Company Type: Tier 1 - 26%, Tier 2 - 44%, and Tier - 30%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America -5 %, Middle East & Africa- 4%, GCC Countries- 1%

The key players in the cancer biomarkers market are Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), QIAGEN (Netherlands), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMerieux SA (US), Becton, Dickinson and Company (US), and Merck Millipore (US).

Research Coverage:

This research report categorizes the cancer biomarkers market by profiling technology (omics technologies, imaging technologies), cancer type (breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkin's lymphoma (NHL), kidney, and other cancers), product type (consumables, instruments, and bioinformatics software), application (diagnostics, research & development, prognostics, risk assessment), end user (diagnostic laboratories, biopharmaceutical companies & CROs, research and academic institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the cancer biomarkers market. A detailed analysis of the key industry players has been conducted to provide insights into their business overviews, solutions, key strategies such as partnerships, collaborations, expansions, agreements, new product launches, and recent developments in the cancer biomarkers market. This report covers a competitive analysis of upcoming startups in the cancer biomarker market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cancer biomarkers market and the subsegments. It will help stakeholders understand the competitive landscape and gain deeper insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (Technological advancements in cancer biomarkers, increasing incidence of cancer, growing adoption of cancer biomarkers in drug discovery and development, increasing investments in research and development for biomarker innovation, growing adoption of non-invasive diagnostics (liquid biopsy), supportive government initiatives and cancer awareness programs), restraints (High capital requirements and long development timelines for biomarker commercialization, unfavorable regulatory frameworks and reimbursement limitations, high cost of biomarker-based diagnostic tests), opportunities (Expanding role of personalized and precision medicine, increasing applications of companion diagnostics in oncology, growth potential in emerging economies, integration of AI and multi-omics approaches in biomarker discovery and analysis), and challenges (Technical challenges related to sample collection, handling, and storage, complexities associated with biomarker validation and standardization, shortage of skilled professionals and technical expertise) influencing the growth of the cancer biomarkers market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the cancer biomarkers market
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the cancer biomarker market across varied regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer biomarkers market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Roche (Switzerland), Thermo Fisher (US), Illumina (US), Agilent Technologies (US), and QIAGEN (Netherlands)

Show more
Product Code: MD 5627

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET
  • 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 CANCER BIOMARKERS MARKET OVERVIEW
  • 3.2 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
  • 3.3 CANCER BIOMARKERS MARKET, BY CANCER TYPE
  • 3.4 CANCER BIOMARKERS MARKET, BY PRODUCT
  • 3.5 CANCER BIOMARKERS MARKET, BY APPLICATION
  • 3.6 CANCER BIOMARKERS MARKET, BY END USER
  • 3.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Technological Advancements in Cancer Biomarkers
      • 4.2.1.2 Increasing incidence of cancer
      • 4.2.1.3 Growing adoption of cancer biomarkers in drug discovery and development
      • 4.2.1.4 Increasing investments in research and development for biomarker innovation
      • 4.2.1.5 Growing Adoption of Non-Invasive Diagnostics (Liquid Biopsy)
      • 4.2.1.6 Supportive Government Initiatives and Cancer Awareness Programs
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High capital requirements and long development timelines for biomarker commercialization
      • 4.2.2.2 Unfavorable regulatory frameworks and reimbursement limitations
      • 4.2.2.3 High Cost of Biomarker-Based Diagnostic Tests
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expanding role of personalized and precision medicine
      • 4.2.3.2 Increasing applications of companion diagnostics in oncology
      • 4.2.3.3 Growth potential in emerging economies
      • 4.2.3.4 Integration of AI and Multi-Omics Approaches in Biomarker Discovery and Analysis
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Technical challenges related to sample collection, handling, and storage
      • 4.2.4.2 Complexities associated with biomarker validation and standardization
      • 4.2.4.3 Shortage of skilled professionals and technical expertise
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN CANCER BIOMARKERS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 SINTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 382200)
    • 5.7.2 EXPORT SCENARIO (HS CODE 382200)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF 2025 US TARIFF ON CANCER BIOMARKERS MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON REGION
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Diagnostic Laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 NEXT-GENERATION SEQUENCING
    • 6.1.2 POLYMERASE CHAIN REACTION
    • 6.1.3 IMMUNOASSAYS
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 BIOINFORMATICS PLATFORMS
    • 6.2.2 MASS SPECTROMETRY
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 LIQUID BIOPSY TECHNOLOGIES
    • 6.3.2 MICROARRAY TECHNOLOGIES
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF KEY PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON CANCER BIOMARKERS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 7.1 DECISION-MAKING PROCESS
  • 7.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 7.2.2 BUYING CRITERIA
  • 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 7.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 7.5 MARKET PROFITABILITY
    • 7.5.1 REVENUE POTENTIAL
    • 7.5.2 COST DYNAMICS
    • 7.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

8 CANCER BIOMARKERS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 OMICS TECHNOLOGIES
    • 8.2.1 PROTEOMICS
      • 8.2.1.1 Immunoassays
        • 8.2.1.1.1 Facilitate diagnosis of cancer at early stage
      • 8.2.1.2 Mass spectrometry
        • 8.2.1.2.1 High specificity of mass spectroscopy to drive adoption
      • 8.2.1.3 2D gel electrophoresis
        • 8.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
      • 8.2.1.4 Protein microarrays
        • 8.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
      • 8.2.1.5 Other proteomic technologies
    • 8.2.2 GENOMICS
      • 8.2.2.1 Next-generation sequencing
        • 8.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
      • 8.2.2.2 Polymerase chain reaction
        • 8.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
      • 8.2.2.3 In situ hybridization
        • 8.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
    • 8.2.3 OTHER OMICS TECHNOLOGIES
  • 8.3 IMAGING TECHNOLOGIES
    • 8.3.1 ULTRASOUND IMAGING
      • 8.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
    • 8.3.2 COMPUTED TOMOGRAPHY
      • 8.3.2.1 Technological advancements to drive adoption
    • 8.3.3 MAGNETIC RESONANCE IMAGING
      • 8.3.3.1 Growing preference for open MRIs to support market growth
    • 8.3.4 POSITRON EMISSION TOMOGRAPHY
      • 8.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
    • 8.3.5 MAMMOGRAPHY
      • 8.3.5.1 Advanced technologies like 3D mammography to support market growth

9 CANCER BIOMARKERS MARKET, BY CANCER TYPE

  • 9.1 INTRODUCTION
  • 9.2 BREAST CANCER
    • 9.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
  • 9.3 LUNG CANCER
    • 9.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
  • 9.4 COLORECTAL CANCER
    • 9.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
  • 9.5 PROSTATE CANCER
    • 9.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
  • 9.6 MELANOMA
    • 9.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
  • 9.7 LEUKEMIA
    • 9.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
  • 9.8 THYROID CANCER
    • 9.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
  • 9.9 BLADDER CANCER
    • 9.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
  • 9.10 NON-HODGKIN'S LYMPHOMA
    • 9.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
  • 9.11 KIDNEY CANCER
    • 9.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
  • 9.12 OTHER CANCERS

10 CANCER BIOMARKERS MARKET, BY PRODUCT

  • 10.1 INTRODUCTION
  • 10.2 CONSUMABLES
    • 10.2.1 KITS & REAGENTS
      • 10.2.1.1 Ease of use to support adoption
    • 10.2.2 ANTIBODIES
      • 10.2.2.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
    • 10.2.3 PROBES
      • 10.2.3.1 Need for probes in assay tests for cancer detection to support market growth
  • 10.3 INSTRUMENTS
    • 10.3.1 IMAGING INSTRUMENTS
      • 10.3.1.1 Technological advancements in imaging instruments to drive growth
    • 10.3.2 PATHOLOGY-BASED INSTRUMENTS
      • 10.3.2.1 Rising demand for cancer diagnosis to drive market
    • 10.3.3 BIOPSY INSTRUMENTS
      • 10.3.3.1 Increasing prevalence of cancer to drive growth
  • 10.4 BIOINFORMATICS SOFTWARE
    • 10.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET

11 CANCER BIOMARKERS MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 DIAGNOSTICS
    • 11.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
  • 11.3 RESEARCH & DEVELOPMENT
    • 11.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
  • 11.4 PROGNOSTICS
    • 11.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
  • 11.5 RISK ASSESSMENT
    • 11.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
  • 11.6 OTHER APPLICATIONS

12 CANCER BIOMARKERS MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 DIAGNOSTIC LABORATORIES
    • 12.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
  • 12.3 BIOPHARMACEUTICAL COMPANIES AND CROS
    • 12.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
  • 12.4 RESEARCH AND ACADEMIC INSTITUTES
    • 12.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
  • 12.5 OTHER END USERS

13 CANCER BIOMARKERS MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 US
      • 13.2.1.1 High adoption of precision oncology and biomarker-driven therapies to drive market growth
    • 13.2.2 CANADA
      • 13.2.2.1 Government Initiatives Driving Biomarker Growth
  • 13.3 EUROPE
    • 13.3.1 GERMANY
      • 13.3.1.1 High Healthcare Spending Driving Biomarker Adoption
    • 13.3.2 UK
      • 13.3.2.1 Rising Cancer Incidence Driving Biomarker Adoption
    • 13.3.3 FRANCE
      • 13.3.3.1 Government Funding Supporting Biomarker Market Growth
    • 13.3.4 ITALY
      • 13.3.4.1 Growing geriatric population to support market growth
    • 13.3.5 SPAIN
      • 13.3.5.1 Rising emphasis on personalized medicine to drive market growth
    • 13.3.6 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 CHINA
      • 13.4.1.1 Rising cancer burden and strong government support to drive market growth
    • 13.4.2 JAPAN
      • 13.4.2.1 Strong healthcare investment to drive market growth
    • 13.4.3 INDIA
      • 13.4.3.1 Rising cancer burden and expanding healthcare investments to drive market growth
    • 13.4.4 AUSTRALIA
      • 13.4.4.1 Rising cancer burden and strong government investments to drive market growth
    • 13.4.5 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 BRAZIL
      • 13.5.1.1 Rising cancer incidence to drive market growth
    • 13.5.2 MEXICO
      • 13.5.2.1 Expanding healthcare access and rising cancer burden to drive market growth
    • 13.5.3 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 EMERGING PRECISION MEDICINE INITIATIVES TO DRIVE MARKET GROWTH
  • 13.7 GCC COUNTRIES
    • 13.7.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER BIOMARKERS MARKET
  • 14.3 REVENUE ANALYSIS, 2023-2025
  • 14.4 MARKET SHARE ANALYSIS, 2025
    • 14.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
    • 14.4.2 US: MARKET SHARE ANALYSIS, 2025
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 14.5.5.1 Company footprint
      • 14.5.5.2 Regional footprint
      • 14.5.5.3 Product footprint
      • 14.5.5.4 Profiling Technology footprint
      • 14.5.5.5 Application footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 14.6.5.1 Detailed list of key startups/SMEs
      • 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
      • 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
  • 14.7 COMPANY VALUATION & FINANCIAL METRICS
    • 14.7.1 FINANCIAL METRICS
    • 14.7.2 COMPANY VALUATION
  • 14.8 BRAND/PRODUCT COMPARISON
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT LAUNCHES & APPROVALS
    • 14.9.2 DEALS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 F. HOFFMANN-LA ROCHE AG
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Product launches & approvals
        • 15.1.1.3.2 Deals
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Key strengths
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses and competitive threats
    • 15.1.2 THERMO FISHER SCIENTIFIC
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Product launches & approvals
        • 15.1.2.3.2 Deals
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Key strengths
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses & competitive threats
    • 15.1.3 ILLUMINA, INC.
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products & services offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Product launches & approvals
        • 15.1.3.3.2 Deals
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Key strengths
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses and competitive threats
    • 15.1.4 AGILENT TECHNOLOGIES, INC.
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products & services offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Product launches & approvals
        • 15.1.4.3.2 Deals
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Key strengths
        • 15.1.4.4.2 Strategic choices
        • 15.1.4.4.3 Weaknesses and competitive threats
    • 15.1.5 QIAGEN
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products & services offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Product launches & approvals
        • 15.1.5.3.2 Deals
      • 15.1.5.4 MnM view
        • 15.1.5.4.1 Key strengths
        • 15.1.5.4.2 Strategic choices
        • 15.1.5.4.3 Weaknesses & competitive threats
    • 15.1.6 BIO-RAD LABORATORIES, INC.
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products & services offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Deals
    • 15.1.7 DANAHER CORPORATION
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
    • 15.1.8 ABBOTT LABORATORIES
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Deals
    • 15.1.9 BIOMERIEUX
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products & services offered
    • 15.1.10 MERCK KGAA
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products & services offered
      • 15.1.10.3 Recent developments
        • 15.1.10.3.1 Product launches & approvals
    • 15.1.11 SIEMENS HEALTHINEERS AG
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
    • 15.1.12 BECTON, DICKINSON AND COMPANY
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
  • 15.2 OTHER PLAYERS
    • 15.2.1 MYRIAD GENETICS
    • 15.2.2 SYSMEX CORPORATION
    • 15.2.3 HOLOGIC, INC.
    • 15.2.4 QUEST DIAGNOSTICS
    • 15.2.5 CENTOGENE N.V.
    • 15.2.6 BIOGENEX
    • 15.2.7 R&D SYSTEMS, INC.
    • 15.2.8 BIOVISION INC.
    • 15.2.9 OLINK
    • 15.2.10 ASURAGEN, INC.
    • 15.2.11 MESO SCALE DIAGNOSTICS, LLC
    • 15.2.12 INVIVOSCRIBE, INC.
    • 15.2.13 INOVIQ LTD.
    • 15.2.14 NANTOMICS

16 RESEARCH METHODOLOGY

  • 16.1 RESEARCH DATA
    • 16.1.1 SECONDARY DATA
      • 16.1.1.1 List of secondary sources
      • 16.1.1.2 Key data from secondary sources
    • 16.1.2 PRIMARY DATA
      • 16.1.2.1 List of primary sources
      • 16.1.2.2 Key data from primary sources
      • 16.1.2.3 Key industry insights
      • 16.1.2.4 Breakdown of primary interviews
  • 16.2 MARKET SIZE ESTIMATION
    • 16.2.1 TOTAL MARKET SIZE: CANCER BIOMARKERS MARKET
    • 16.2.2 BOTTOM-UP APPROACH
      • 16.2.2.1 Approach 1: Revenue estimation of key players
      • 16.2.2.2 Approach 2: Study of annual reports and investor presentations
      • 16.2.2.3 Approach 3: Primary interviews
      • 16.2.2.4 Growth forecast
      • 16.2.2.5 CAGR projections
    • 16.2.3 TOP-DOWN APPROACH
  • 16.3 DATA TRIANGULATION
  • 16.4 RESEARCH ASSUMPTIONS
    • 16.4.1 STUDY-RELATED ASSUMPTIONS
  • 16.5 STUDY ASSUMPTIONS
    • 16.5.1 PARAMETRIC ASSUMPTIONS
    • 16.5.2 GROWTH RATE ASSUMPTIONS
  • 16.6 RESEARCH LIMITATIONS
  • 16.7 RISK ASSESSMENT

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS
Show more
Product Code: MD 5627

List of Tables

  • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • TABLE 2 ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+] ALL CANCERS
  • TABLE 3 CANCER INCIDENCE, BOTH SEXES, IN 2022
  • TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
  • TABLE 5 IMPACT OF PORTER'S FIVE FORCES ON CANCER BIOMARKERS MARKET
  • TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 8 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 12 CANCER BIOMARKERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 13 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 14 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 17 CANCER BIOMARKERS MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 19 KEY PATENTS IN CANCER BIOMARKERS MARKET, 2022-2026
  • TABLE 20 KEY COMPANIES IMPLEMENTING AI IN CANCER BIOMARKERS MARKET
  • TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
  • TABLE 22 KEY BUYING CRITERIA, BY PRODUCT
  • TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 24 CANCER BIOMARKERS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 25 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 26 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 27 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 28 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 29 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 31 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 32 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 33 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 35 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 37 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 38 IMMUNOASSAYS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 39 MASS SPECTROMETRY MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 40 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 41 PROTEIN MICROARRAYS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 42 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 43 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 44 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 45 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 46 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 48 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 49 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 50 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 51 IN SITU HYBRIDIZATION MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 52 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 54 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 56 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 57 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 58 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 59 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 60 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 62 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 63 ULTRASOUND IMAGING MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 64 NORTH AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 65 EUROPE: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 67 LATIN AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 68 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 69 NORTH AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 70 EUROPE: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 72 LATIN AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 73 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 74 NORTH AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 75 EUROPE: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 77 LATIN AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 78 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 79 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 80 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 82 LATIN AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 83 MAMMOGRAPHY MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 84 NORTH AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 85 EUROPE: MAMMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: MAMMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 87 LATIN AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 88 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 89 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 90 BREAST CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 92 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 94 LATIN AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 95 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 96 LUNG CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 97 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 98 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 100 LATIN AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 101 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 102 COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 103 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 104 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 106 LATIN AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 107 PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 108 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 109 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 111 LATIN AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 112 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
  • TABLE 113 MELANOMA BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 114 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 115 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 117 LATIN AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 118 LEUKEMIA BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 119 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 120 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 122 LATIN AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 123 THYROID CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 124 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 125 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 127 LATIN AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 128 BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 129 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 130 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 132 LATIN AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 133 NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 134 NORTH AMERICA: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 135 EUROPE: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 137 LATIN AMERICA: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 138 KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 139 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 140 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 141 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 142 LATIN AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 143 OTHER CANCERS BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 144 NORTH AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 145 EUROPE: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 147 LATIN AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 148 CANCER BIOMARKERS MARKET, BY PRODUCTS, 2024-2032 (USD MILLION)
  • TABLE 149 CANCER BIOMARKERS CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 150 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 151 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 152 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 154 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 155 KITS & REAGENTS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 156 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 157 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 159 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 160 ANTIBODIES MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 161 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 162 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 164 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 165 PROBES MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 166 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 167 EUROPE: PROBES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 169 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 170 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 171 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 172 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 173 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 175 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 176 IMAGING INSTRUMENTS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 177 NORTH AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 178 EUROPE: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 180 LATIN AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 181 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 182 NORTH AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 183 EUROPE: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 185 LATIN AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 186 BIOPSY INSTRUMENTS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 187 NORTH AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 188 EUROPE: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 190 LATIN AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 191 BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 192 NORTH AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 193 EUROPE: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 195 LATIN AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 196 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 197 CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 198 NORTH AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 199 EUROPE: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 201 LATIN AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 202 CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 203 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 204 EUROPE: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 206 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 207 CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 208 NORTH AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 209 EUROPE: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 211 LATIN AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 212 CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 213 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 214 EUROPE: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 216 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 217 CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 218 NORTH AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 219 EUROPE: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 221 LATIN AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 222 CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 223 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 224 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 225 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 227 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 228 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 229 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 230 EUROPE: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 232 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 233 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 234 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 235 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 237 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 238 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 239 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 240 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 242 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 243 CANCER BIOMARKERS MARKET, BY REGION, 2024-2032 (USD MILLION)
  • TABLE 244 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
  • TABLE 245 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 246 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 247 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 248 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 249 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 250 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 251 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 252 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 253 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 254 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 255 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 256 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 257 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 258 US - NUMBER OF CANCER BIOMARKER TESTS FOR NON-SMALL CELL LUNG CANCER, BY SAMPLE TYPE, 2024-2032 (TESTS)
  • TABLE 259 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 260 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 261 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 262 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 263 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 264 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 265 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 266 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 267 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 268 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 269 US: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 270 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 271 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 272 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 273 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 274 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 275 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 276 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 277 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 278 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 279 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 280 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 281 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE
  • TABLE 282 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 283 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 284 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 285 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 286 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 287 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 288 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 289 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 290 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 291 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 292 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 293 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 294 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 295 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 296 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 297 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 298 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 299 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 300 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 301 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 302 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 303 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 304 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 305 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 306 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 307 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 308 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 309 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 310 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 311 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 312 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 313 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 314 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 315 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 316 UK: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 317 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 318 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 319 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 320 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 321 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 322 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 323 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 324 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 325 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 326 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 327 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 328 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 329 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 330 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 331 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 332 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 333 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 334 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 335 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 336 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 337 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 338 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 339 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 340 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 341 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 342 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 343 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 344 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 345 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 346 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 347 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 348 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 349 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 350 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 351 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 352 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 353 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 354 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 355 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 356 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 357 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 358 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 359 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 360 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 361 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 362 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 363 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 364 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 365 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 367 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 368 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 369 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 370 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 371 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 372 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 373 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 374 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 375 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 376 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 377 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 378 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 379 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 380 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 381 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 382 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 383 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 384 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 385 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 386 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 387 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 388 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 389 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 390 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 391 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 392 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 393 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 394 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 395 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 396 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 397 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 398 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 399 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 400 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 401 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 402 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 403 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 404 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 405 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 406 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 407 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 408 AUSTRALIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 409 AUSTRALIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 410 AUSTRALIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 411 AUSTRALIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 412 AUSTRALIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 413 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 414 AUSTRALIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 415 AUSTRALIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 416 AUSTRALIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 417 AUSTRALIA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 418 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 419 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 420 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 421 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 422 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 423 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 424 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 425 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 426 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 427 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 428 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 429 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 430 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024-2032 (USD MILLION)
  • TABLE 431 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 432 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 433 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 434 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 435 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 436 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 437 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 438 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 439 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 440 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 441 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 442 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 443 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 444 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 445 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 446 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 447 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 448 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 449 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 450 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 451 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 452 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 453 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 454 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 455 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 456 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 457 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 458 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 459 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 460 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 461 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 462 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 463 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 464 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 465 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 466 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 467 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 468 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 469 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 470 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 471 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 472 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 473 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 474 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 475 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 476 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 477 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 478 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 479 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 480 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 481 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 482 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 483 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 484 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 485 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 486 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024-2032 (USD MILLION)
  • TABLE 487 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 488 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 489 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 490 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 491 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024-2032 (USD MILLION)
  • TABLE 492 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024-2032 (USD MILLION)
  • TABLE 493 GCC COUNTRIES: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 494 GCC COUNTRIES: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024-2032 (USD MILLION)
  • TABLE 495 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024-2032 (USD MILLION)
  • TABLE 496 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY END USER, 2024-2032 (USD MILLION)
  • TABLE 497 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CANCER BIOMARKERS MARKET, JANUARY 2023-APRIL 2026
  • TABLE 498 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
  • TABLE 499 CANCER BIOMARKER MARKET: REGIONAL FOOTPRINT, 2025
  • TABLE 500 CANCER BIOMARKER MARKET: PRODUCT FOOTPRINT, 2025
  • TABLE 501 CANCER BIOMARKER MARKET: PROFILING TECHNOLOGY FOOTPRINT, 2025
  • TABLE 502 CANCER BIOMARKER MARKET: APPLICATION FOOTPRINT, 2025
  • TABLE 503 CANCER BIOMARKER MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025
  • TABLE 504 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2), 2025
  • TABLE 505 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2), 2025
  • TABLE 506 CANCER BIOMARKER MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 507 CANCER BIOMARKER MARKET: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 508 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
  • TABLE 509 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED
  • TABLE 510 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES & APPROVALS
  • TABLE 511 F. HOFFMANN-LA ROCHE AG: DEALS
  • TABLE 512 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 513 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 514 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 515 THERMO FISHER SCIENTIFIC INC.: DEALS
  • TABLE 516 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 517 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 518 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 519 ILLUMINA, INC.: DEALS
  • TABLE 520 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 521 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 522 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 523 AGILENT TECHNOLOGIES, INC.: DEALS
  • TABLE 524 QIAGEN: COMPANY OVERVIEW
  • TABLE 525 QIAGEN: PRODUCTS & SERVICES OFFERED
  • TABLE 526 QIAGEN: PRODUCT LAUNCHES & APPROVALS
  • TABLE 527 QIAGEN: DEALS
  • TABLE 528 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
  • TABLE 529 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 530 BIO-RAD LABORATORIES, INC.: DEALS
  • TABLE 531 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 532 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 533 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 534 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 535 ABBOTT LABORATORIES: DEALS
  • TABLE 536 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 537 BIOMERIEUX: PRODUCTS & SERVICES OFFERED
  • TABLE 538 MERCK KGAA: BUSINESS OVERVIEW
  • TABLE 539 MERCK KGAA: PRODUCTS & SERVICES OFFERED
  • TABLE 540 MERCK KGAA: PRODUCT LAUNCHES & APPROVALS
  • TABLE 541 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 542 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 543 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 544 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 545 MYRIAD GENETICS: COMPANY OVERVIEW
  • TABLE 546 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 547 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 548 QUEST DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 549 CENTOGENE N.V.: COMPANY OVERVIEW
  • TABLE 550 BIOGENEX: COMPANY OVERVIEW
  • TABLE 551 R&D SYSTEMS, INC.: COMPANY OVERVIEW
  • TABLE 552 BIOVISION INC.: COMPANY OVERVIEW
  • TABLE 553 OLINK: COMPANY OVERVIEW
  • TABLE 554 ASURAGEN, INC.: COMPANY OVERVIEW
  • TABLE 555 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW
  • TABLE 556 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
  • TABLE 557 INOVIQ LTD.: COMPANY OVERVIEW
  • TABLE 558 NANTOMICS: COMPANY OVERVIEW
  • TABLE 559 KEY DATA FROM PRIMARY SOURCES
  • TABLE 560 CANCER BIOMARKERS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
  • FIGURE 2 STUDY YEARS CONSIDERED
  • FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • FIGURE 4 GLOBAL CANCER BIOMARKERS MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023-2026
  • FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER BIOMARKERS MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN CANCER BIOMARKERS MARKET, 2025
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 9 RISING PREVALENCE OF CANCER TO DRIVE MARKET
  • FIGURE 10 OMICS TECHNOLOGIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 CONSUMABLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 13 DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 16 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17 CANCER BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 18 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 19 CANCER BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 20 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 21 CANCER BIOMARKERS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN CANCER BIOMARKERS MARKET
  • FIGURE 23 PATENT ANALYSIS FOR CANCER BIOMARKERS, JANUARY 2016-DECEMBER 2025
  • FIGURE 24 MARKET POTENTIAL OF AI IN CANCER BIOMARKERS MARKET
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT
  • FIGURE 27 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023-2025 (USD MILLION)
  • FIGURE 30 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, 2025
  • FIGURE 31 US: CANCER BIOMARKER MARKET SHARE ANALYSIS, 2025
  • FIGURE 32 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 33 CANCER BIOMARKERS MARKET: COMPANY FOOTPRINT, 2025
  • FIGURE 34 CANCER BIOMARKER MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 35 EV/EBITDA OF KEY VENDORS, 2026
  • FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026
  • FIGURE 37 CANCER BIOMARKER MARKET: BRAND/PRODUCT COMPARISON FOR CANCER BIOMARKER
  • FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025)
  • FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT, 2025
  • FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT, 2025
  • FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2025
  • FIGURE 42 QIAGEN: COMPANY SNAPSHOT, 2025
  • FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT, 2025
  • FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025
  • FIGURE 46 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT, 2025
  • FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025
  • FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025
  • FIGURE 50 RESEARCH DESIGN
  • FIGURE 51 KEY DATA FROM SECONDARY SOURCES
  • FIGURE 52 LIST OF PRIMARY SOURCES
  • FIGURE 53 KEY INDUSTRY INSIGHTS
  • FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 55 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
  • FIGURE 56 CAGR PROJECTIONS
  • FIGURE 57 TOP-DOWN APPROACH
  • FIGURE 58 DATA TRIANGULATION
  • FIGURE 59 PARAMETRIC ASSUMPTIONS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!